Status:

UNKNOWN

Clinical Trial of SAHA in Patients With Breast Cancer

Lead Sponsor:

National University Hospital, Singapore

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Purpose: * evaluate the safety of Vorinostat. * evaluate the effectiveness of Vorinostat in treating breast cancer * evaluate how the study subject's body reacts to Vorinostat, how these reactions re...

Detailed Description

Breast cancer is sensitive to a range of chemotherapeutics agents, but despite initial sensitivity, resistance typically emerges, resulting in disease relapse or progression. Exploration of novel clas...

Eligibility Criteria

Inclusion

  • Key
  • Cytologically or histologically confirmed adenocarcinoma of the breast that is recurrent and/or metastatic
  • Must have measurable disease as defined by RECIST criteria
  • No more than 2 prior chemotherapy for recurrent and/or metastatic disease excluding neoadjuvant or adjuvant chemotherapy
  • Previously received anthracycline- and taxane-containing chemotherapy for treatment of breast cancer in the neoadjuvant, adjuvant, or metastatic setting
  • Must be able to swallow capsules
  • Adequate bone marrow reserve and liver function
  • Women in reproductive age group must agree to practice effective contraception during the entire study period unless documentation of infertility exists.
  • Key

Exclusion

  • Prior treatment with any HDAC inhibitor. Patients who have received such agents for other indications, e.g. epilepsy, may enroll in the trial after a 30 day washout period.
  • Known CNS involvement by tumor
  • Concurrent use of oral retinoids or any vitamin A, other than a single multivitamin tablet daily
  • Acute infection requiring intravenous antibiotics or antifungal agents,known HIV infection, active hepatitis B and/or hepatitis C infection
  • Uncontrolled intercurrent illness
  • Cancer other than breast cancer with the exception of basal cell carcinoma or disease that has been in remission for ≥5 years
  • Pregnant or lactating women

Key Trial Info

Start Date :

January 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2015

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00416130

Start Date

January 1 2007

End Date

January 1 2015

Last Update

December 10 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

National University Hospital

Singapore, Singapore, 149547

2

National Cancer Centre

Singapore, Singapore, 169610